The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases.
The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases.
复制标题
RTOG 0614 和 RTOG 0933 试验对常规临床实践的影响：美国美金刚使用情况调查和 IMRT 计划对接受全脑放疗的脑转移患者的海马保留。
DOI：
10.1016/j.cct.2015.12.013
复制
发表时间：
2016
影响因子：
2.2
通讯作者：
Stanic,Sinisa
中科院分区：
文献类型：
--
作者：
Slade,AlexanderN;Stanic,Sinisa
IntroductionTwo最近的临床试验，第三阶段RTOG 0614和第二阶段RTOG 0933，显示了一定的有效性美金刚胺和IMRT规划海马保留，在接受全脑放疗（WBRT）的脑转移瘤的患者，但是，他们在常规临床实践中的使用是unknow.MethodsA调查发送到1933放射肿瘤学家在美国。收集的数据包括利用美金刚胺和海马保留，原因通过和不通过，和人口统计variables.ResultsA共196放射肿瘤学家回答了调查，64%的报告使用美金刚胺几乎没有接受WBRT脑转移的患者，只有11%考虑美金刚胺为< 10%的患者。不使用美金刚胺的最常见原因是患者的体能状态不佳和预期寿命有限。同样，56%的放射肿瘤学家不会改变他们的临床实践，根据RTOG 0933的结果，在接受WBRT的患者中纳入海马保留IMRT。71%的放射肿瘤学家支持在III期试验中进一步验证海马保留，而42%的放射肿瘤学家支持在III期试验中进一步探索美金刚用于此目的。在常规临床实践中采用海马保留概念之前，支持在III期试验中进一步验证海马保留概念。
IntroductionTwo recent clinical trials, phase III RTOG 0614 and phase II RTOG 0933, showed some effectiveness of Memantine and IMRT planning for hippocampus sparing, among patients receiving whole brain radiotherapy (WBRT) for brain metastases; however, their use in routine clinical practice is unknown.MethodsA survey was sent to 1933 radiation oncologists in the US. Data collected included utilization of Memantine and hippocampus sparing, reasons for adoption and non-adoption, and demographic variables.ResultsA total of 196 radiation oncologists responded to the survey, with 64% reporting using Memantine in almost none of the patients receiving WBRT for brain metastases, and only 11% considering Memantine for < 10% of their patients. The most common reason for not using Memantine was a poor patient performance status, and limited life expectancy. Likewise, 56% of radiation oncologists would not change their clinical practice to include hippocampus sparing IMRT in patients receiving WBRT based on the results of RTOG 0933. Further validation of hippocampus sparing in a phase III trial was supported by 71% of radiation oncologists, whereas further exploration of Memantine for this purpose in a phase III trial was supported by 42%.ConclusionsAt this time, the majority of surveyed radiation oncologists in the US do not use Memantine, or IMRT planning for hippocampus sparing in patients receiving WBRT. Further validation of the hippocampus sparing concept in a phase III trial was supported, before adopting it in routine clinical practice.